Department of Urology, Harran University School of Medicine, Sanliurfa, Turkey.
Department of Urology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey.
Int Braz J Urol. 2018 May-Jun;44(3):600-607. doi: 10.1590/S1677-5538.IBJU.2017.0668.
Apoptosis effect of oral alpha-blockers is known in the prostate. Apoptosis index of silodosin has not been proved, yet. Aims are to present apoptosis index of silodosin in prostate and to compare this with other currently used alpha-blocker's apoptosis indexes together with their clinical effects.
Benign prostatic hyperplasia (BPH) patients were enrolled among those admitted to urology outpatient clinic between June 2014 and June 2015. Study groups were created according to randomly prescribed oral alpha-blocker drugs as silodosin 8mg (Group 1; n=24), tamsulosin 0.4mg (Group 2; n=30), alfuzosin 10mg (Group 3; n=25), doxazosin 8mg (Group 4; n=22), terazosin 5mg (Group 5; n=15). Patients who refused to use any alpha-blocker drug were included into Group 6 as control group (n=16). We investigated apoptosis indexes of the drugs in prostatic tissues that were taken from patient's surgery (transurethral resection of prostate) and/or prostate biopsies. Immunochemical dyeing, light microscope, and Image Processing and Analysis in Java were used for evaluations. Statistical significant p was p<0.05.
There were 132 patients with mean follow-up of 4.2±2.1 months. Pathologist researched randomly selected 10 areas in each microscope set. Group 1 showed statistical significant difference apoptosis index in immunochemical TUNEL dyeing and image software (p<0.001). Moreover, we determined superior significant development in parameters as uroflowmetry, quality of life scores, and international prostate symptom score in Group 1.
Silodosin has higher apoptosis effect than other alpha-blockers in prostate. Thus, clinic improvement with silodosin was proved by histologic studies. Besides, static factor of BPH may be overcome with creating apoptosis.
已知口服α受体阻滞剂可诱导前列腺细胞凋亡。然而,关于西洛多辛的凋亡指数尚未得到证实。本研究旨在探讨西洛多辛对前列腺细胞凋亡的影响,并与其他目前常用的α受体阻滞剂的凋亡指数及其临床疗效进行比较。
本研究纳入 2014 年 6 月至 2015 年 6 月期间在泌尿科门诊就诊的良性前列腺增生(BPH)患者。根据随机开具的口服α受体阻滞剂药物将患者分为 6 组:西洛多辛 8mg 组(1 组,n=24)、坦索罗辛 0.4mg 组(2 组,n=30)、阿夫唑嗪 10mg 组(3 组,n=25)、多沙唑嗪 8mg 组(4 组,n=22)、特拉唑嗪 5mg 组(5 组,n=15)。拒绝使用任何α受体阻滞剂的患者被纳入对照组(6 组,n=16)。我们检测了前列腺组织中的凋亡指数,这些组织取自患者的手术(经尿道前列腺切除术)和/或前列腺活检。免疫化学染色、光学显微镜和 Java 图像处理与分析用于评估。统计学显著性 p 值为 p<0.05。
共纳入 132 例患者,平均随访时间为 4.2±2.1 个月。病理学家在每台显微镜中随机选择 10 个区域进行研究。1 组的免疫组织化学 TUNEL 染色和图像软件的凋亡指数存在统计学差异(p<0.001)。此外,我们发现 1 组在尿流率、生活质量评分和国际前列腺症状评分等参数方面有显著改善。
与其他α受体阻滞剂相比,西洛多辛在前列腺中具有更高的凋亡作用。因此,组织学研究证实了西洛多辛的临床改善作用。此外,通过诱导细胞凋亡可能克服 BPH 的静态因素。